[Growth hormone levels in the blood serum and cerebrospinal fluid of patients with multiple sclerosis]. 1987

S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
Klinicznego Oddziału Neurologii w Kielcach Katedry Nauczania Klinicznego AM im. M. Kopernika w Krakowie.

In 1984 the authors determined by radioimmunoassay (ORIPI-RIA kit) the serum growth hormone levels in 35 patients with multiple sclerosis (20 M, 15 F) aged from 20 to 54 years, and in 10 cases the determination was carried out in the cerebrospinal fluid (CSF). The control group comprised 40 patients with ischialgia or neuroses. The normal range of GH values in the serum determined with this kit was from 0 to 80 microIU/ml, and the laboratory normal range was from 0 to 10 microIU/ml. The normal GH value for the CSF is being established (calculations based on mean values). No significant differences were observed in the GH concentrations in the serum between the patients and the control group, and between males and females in either group. No significant differences were found also in the GH level in the CSF of males and females with multiple sclerosis. Treatment with corticosteroids received by over 80% of the patients (at least 6 months before the study) caused no significant rise in GH concentration. However, an increasing tendency was observed of GH concentration in patients which requires confirmation in a greater number of cases.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin

Related Publications

S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
April 1991, Journal of neuroimmunology,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
January 1978, Neurologia i neurochirurgia polska,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
March 2006, Clinical neurology and neurosurgery,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
January 2009, Clinical chemistry and laboratory medicine,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
June 2008, Clinical neurology and neurosurgery,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
December 1988, Annals of neurology,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
January 1999, European neurology,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
October 2019, Multiple sclerosis (Houndmills, Basingstoke, England),
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
April 1964, Journal of neurology, neurosurgery, and psychiatry,
S Nowak, and D Kowalski, and K Kowalska, and B Błaszczyk, and E Banasinska
December 1998, Neuroscience letters,
Copied contents to your clipboard!